Posted in | News | Fullerenes | Nanobusiness

Unidym Signs Exclusive License Agreement with Nano-C for Patents Covering Fullerene Derivative

Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has entered an exclusive license agreement with Nano-C for patents covering fullerene derivatives. The license provides Nano-C exclusive rights to U.S. Patent No. 5,739,376 and foreign counterparts in the field of photovoltaics.

In recent years, researchers and companies seeking to commercialize novel thin film Organic Photovoltaic (OPV) solar technologies have focused on using fullerene derivatives as the n-type semiconductor in bulk heterojunction organic solar cells. The use of fullerenes as the electron acceptor and transporter results in higher quantum efficiencies of the cells.

“The ‘376 patent family covers many of the fullerene derivatives used in OPV, including the widely used C60 and C70 PCBM compounds,” stated Viktor Vejins, CEO of Nano-C. “We are delighted to add this patent to our growing IP portfolio, which further strengthens our position in fullerene manufacture, purification, separation and derivatization. As a fully integrated supplier, the exclusive rights obtained by Nano-C under this agreement will benefit our customers as they commercialize OPV-based devices.”

“We chose to execute this license agreement because we believe Nano-C is the leader in fullerene technology and products for the emerging thin film solar industry,” stated Mark Tilley, CEO of Unidym. “We are pleased to enable Nano-C to unleash the potential of modified fullerenes in thin film solar.”

Unidym will also cooperate with Nano-C to supply a variety of patented derivatives to customers for uses beyond Photovoltaics. This cooperation will expand the market for devices that use this family of patents. Terms of the agreement were not disclosed.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.